Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Pentagon advances Golden Dome missile defense with new Space Force contracts - 2Different Film Classification: What's Your Go-To for Amusement
- 3Famous Places to get-away for Americans
- 46 Agreeable Earphones To Wear
- 5Beyond the habitable zone: Exoplanet atmospheres are the next clue to finding life on planets orbiting distant stars
- Little Italy Mercato brings fresh food and community to downtown San Diego
- A definitive Manual for the 5 Off-road Bicycles Available
- Wait, it's 'Harry Potter and the Philosopher's Stone'? Why the new HBO series name is significant to Americans
- Honda’s Biggest Flex Isn’t Its Superbikes, It’s Selling 500K Bikes In One Month
- OPEC’s No. 2 Producer Burns Its Own Gas—Then Buys Iran’s
- Data centers in space: Will 2027 really be the year AI goes to orbit?
- Report: Thailand strikes deal with Iran for safe passage of Hormuz
- The most effective method to Guarantee Thorough Inclusion in Senior Protection.
- Exploring the School Application Cycle: Understudy Bits of knowledge
